Clearmind Medicine Inc. CMND
Clearmind Medicine Inc. (Nasdaq: CMND) is a CNS/neurology/psychiatry drug developer. Its lead program, Psychedelic-derived candidates (e.g. MEAI-based), is in Phase 1 for Alcohol use disorder and other CNS indications.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Lead psychedelic programs | AUD | small molecule | Phase 1 |
Recent results and decisions
- Sep 8, 2026met Part A: all 24 participants across four ascending-dose cohorts completed treatment; primary safety and tolerability endpoint achieved, no SAEs (recap of prior announcement).
The study achieved its primary endpoint of safety and tolerability.
Filing - Sep 8, 2026n/a Yale IRB approved patient recruitment for Parts B and C of the CMND-100 trial.
Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100.
Filing - Apr 14, 2026met Met primary safety and tolerability endpoint in dose-escalation; no serious adverse events in cohort 3 at higher dose.
Meeting the primary safety and tolerability endpoint in this dose-escalation stage, including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD.
Filing
4 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.